1. Home
  2. SABR vs ENTA Comparison

SABR vs ENTA Comparison

Compare SABR & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabre Corporation

SABR

Sabre Corporation

HOLD

Current Price

$1.76

Market Cap

580.9M

Sector

Technology

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.55

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SABR
ENTA
Founded
2006
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
580.9M
374.6M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
SABR
ENTA
Price
$1.76
$14.55
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$2.50
$20.40
AVG Volume (30 Days)
4.9M
111.5K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
283.56
29.93
EPS
1.34
N/A
Revenue
$3,866,956,000.00
$102,814,000.00
Revenue This Year
$7.15
$7.76
Revenue Next Year
$3.40
N/A
P/E Ratio
$1.17
N/A
Revenue Growth
7.46
16.48
52 Week Low
$0.81
$4.83
52 Week High
$3.46
$17.15

Technical Indicators

Market Signals
Indicator
SABR
ENTA
Relative Strength Index (RSI) 62.85 63.55
Support Level $1.72 $13.39
Resistance Level $1.98 $15.52
Average True Range (ATR) 0.11 0.82
MACD 0.02 0.24
Stochastic Oscillator 93.51 87.58

Price Performance

Historical Comparison
SABR
ENTA

About SABR Sabre Corporation

Sabre holds the number-two air booking volume share in the global distribution system industry. The distribution segment represented 80% of total 2025 revenue and airline IT solutions 20% of revenue. The company sold its growing hotel IT solutions division to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: